Frontlight ResearchEarly access
Active, not recruitingNo phase
Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve
Key facts
- Who runs it
- Edwards Lifesciences
- Where
- Ann Arbor, Athens, Atlanta, Carmel, Durham, Milwaukee, Nashville, New York, Newport Beach, Orlando, Palo Alto, Philadelphia, Pittsburgh, Rochester, Salt Lake City, and St Louis, United StatesSee the 20 sitesAlso in 3 other countries, 14 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 504 people enrolled
- Started
- 11 Jan 2023
- Expected to end
- Dec 2035
- Type of study
- Observational
- Treatments tested
- MITRIS RESILIA Mitral Valve, Model 11400M
- Record updated
- 22 May 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- 18 years or older at the time of informed consent
- Has a dysfunctional native or prosthetic mitral valve and requires mitral valve replacement surgery
- Provides written informed consent
- Willingness to follow protocol requirements
Who cannot take part
- Active endocarditis 3 months prior to the procedure
- High predicted risk of mortality prior to procedure; Society of Thoracic Surgeons (STS) Predicted Risk of Mortality (PROM) score of > 8 or; Surgeon estimated risk of mortality of > 8
- Stage 4 renal disease or requiring dialysis
- Less than 2-year life expectancy due to non-cardiovascular life-threatening disease
Where in United States
Also in 3 other countries, 14 sites
- University of MichiganAnn Arbor, United States
- Piedmont Heart InstituteAthens, United States
- Piedmont Heart InstituteAtlanta, United States
- Ascension St. Vincent Heart CenterCarmel, United States
- Duke University Medical CenterDurham, United States
- Aurora St. Luke's Medical CenterMilwaukee, United States
- Ascension Saint ThomasNashville, United States
- TriStar Centennial Medical centerNashville, United States
- Columbia University Irving Medical CenterNew York, United States
- Mount Sinai HospitalNew York, United States
- Weill Cornell MedicineNew York, United States
- Hoag Memorial Hospital PresbyterianNewport Beach, United States
- AdventHealth OrlandoOrlando, United States
- Stanford UniversityPalo Alto, United States
- Hospital of the University of PennsylvaniaPhiladelphia, United States
- Allegheny General HospitalPittsburgh, United States
- UPMC Presbyterian ShadysidePittsburgh, United States
- Mayo Clinic - RochesterRochester, United States
- University of UtahSalt Lake City, United States
- Washington University (Barnes-Jewish Hospital)St Louis, United States
About the trial
What the trial wants to find out
Collect real-world data on acute and long-term safety and performance of the MITRIS RESILIA Mitral Valve, Model 11400M, in subjects requiring replacement of their native or prosthetic mitral valve with or without concomitant procedures.
The group in the trial
- Patients requiring replacement of their native or prosthetic mitral valve
Treatment: MITRIS RESILIA Mitral Valve, Model 11400M
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Global Study Designed to Collect Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve
- Record updated
- 22 May 2026